Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChAdOx2 HAV + MVA HAV
- Development stage
- Unknown
- Lead developer
- HAV Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ChAdOx2 HAV + MVA HAV is a heterologous prime-boost vaccine combination targeting Mycobacterium avium subspecies paratuberculosis (MAP), which is hypothesized to be associated with Crohn's disease. The antigen for both vectored vaccines consists of a 95kDa fusion construct from four MAP genes (1589c/AhpC, MAP 1234/Gsd, 2444c/p12, and 1235/mpa). ChAdOx2 HAV is a replication-deficient simian adenovirus vector used as the prime, while MVA HAV is a highly attenuated poxvirus vector used as the boost. The vaccine combination aims to induce a T cell-mediated immune response against MAP in patients with Crohn's disease.
- Other names
- MVA + HAVMycobacterium avium subspecies paratuberculosis vaccine (MVA vector and ChAdOx2 vector)MAP vaccine (MVA + HAV)
02
Targets
HAV antigens (Hepatitis A virus antigens)
Beyond the preview
Go deeper on ChAdOx2 HAV + MVA HAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ChAdOx2 HAV + MVA HAV.